|
|
 |
Your Online Resource for Diabetes Treatment
Home > Literature
Alerts > Recent Articles
Updated June, 08 2009
Recent Diabetes Articles | 
|
| • |
Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L
Diabetes Care. 2009 Jun 5. [Epub ahead of print] |
| • |
Risk of type 2 diabetes among individuals with high and low glomerular filtration rates
Lorenzo C, Nath SD, Hanley AJ, Abboud HE, Gelfond JA, Haffner SM
Diabetologia. 2009;52(7):1290-1297 |
| • |
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
The BARI 2D Study Group
N Engl J Med. 2009 Jun 7. [Epub ahead of print] |
| • |
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Home PD, Pocock SJ, Beck-Nielsen H, et al, for the RECORD Study Team
Lancet. 2009 Jun 5. [Epub ahead of print] |
| • |
Hypoglycemia unawareness in older compared to middle-aged patients with type 2 diabetes
Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B
Diabetes Care. 2009 Jun 1. [Epub ahead of print] |
| • |
The pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia
Pruski M, Krysiak R, Okopien B
Diabetes Care. 2009 May 12. [Epub ahead of print] |
| • |
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
Rosenstock J, Niggli M, Maldonado-Lutomirsky M
Diabetes, Obesity and Metabolism. 2009 Mar 28. [Epub ahead of print] |
| • |
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
Bosi E, Dotta F, Jia Y, Goodman M
Diabetes, Obesity and Metabolism. 2009;11(5):506-515 |
| • |
Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus
Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B
Am J Cardiol.. 2009;103(10):1364-1367 |
| • |
Poor glycemic control is an independent risk factor for low HDL-C in patients with type 2 diabetes
Gatti A, Maranghi M, Bacci S, et al
Diabetes Care. 2009 Jun 1. [Epub ahead of print] |
| • |
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy L, Casas JP, Hingorani AD, Williams D
Lancet. 2009;373(9677):1773-1779 |
| • |
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Rajamani K, Colman PG, Li LP, et al for the FIELD study investigators
Lancet. 2009;373(9677):1780-1788 |
| • |
Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD)
McEwen LN, Bilik D, Johnson SL, et al
ACC Abstracts of the 48th Scientific Session. 2009;32(6):971-976 |
| • |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide
Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA
ACC Abstracts of the 48th Scientific Session. 2009;32(5):409-418 |
| • |
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Ray KK, Seshasai SR, Wijesuriya S, et al
Lancet. 2009;373(9677):1765-1772 |
| • |
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction
Goyal A, Mehta SR, Gerstein HC, et al
Am Heart J. 2009;157(4):763-770 |
| • |
Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2)
Ramachandran A, Snehalatha C, Mary S, et al
Diabetologia. 2009;52(6):1019-1026 |
| • |
Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men
Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M
Diabetes. 2009;58(5):1212-1221 |
| • |
Elevated A1C in adults without a history of diabetes in the US
Selvin E, Zhu H, Brancati FL
Diabetes Care. 2009;32(5):828-833 |
| • |
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
Dore DD, Seeger JD, Arnold Chan K
Curr Med Res Opin. 2009;25(4):1019-1027 |
| • |
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial
Bunck MC, Diamant M, Cornér A, et al
Diabetes Care. 2009;32(5):762-768 |
| • |
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes: An Overview of Data from PROactive
Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; on behalf of the PROactive investigators
Drug Saf. 2009;32(3):187-202 |
| • |
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Tahrani AA, Piya MK, Barnett AH
Adv Ther. 2009;26(3):249-262 |
| • |
Impact of sitagliptin on markers of beta-cell function: a meta-analysis
Riche DM, East HE, Riche KD
Am J Med Sci. 2009;337(5):321-328 |
| • |
Risk Management and Outcomes of Adverse Events to Pioglitazone in Primary Care in the UK: An Observational Study
Fogg C, Kasliwal R, Shakir SA.
Drug Saf. 2009;32(3):229-237. |
|
